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One of the ultimate goals of successful solid organ transplantation in pediatric recipients is attaining an optimal
final adult height. This manuscript will discuss growth following transplantation in pediatric recipients of
kidney, liver, heart, lung or small bowel transplants. Remarkably similar factors impact growth in all of these
recipients. Age is a primary factor, with younger recipients exhibiting the greatest immediate catch-up growth.
Graft function is a significant contributing factor, with a reduced glomerular filtration rate correlating with
poor growth in kidney recipients and the need for re-transplantation with impaired growth in liver recipients.
The known adverse impact of steroids on growth has led to modification of the steroid dose and even steroid
withdrawal and avoidance. In kidney and liver recipients, this strategy has been associated with the
development of acute rejection. In infant heart transplantation, avoiding maintenance corticosteroid
immunosuppression is associated with normal growth velocity in the majority of patients. With marked
improvements in patient and graft survival rates in pediatric organ recipients, quality of life issues, such as
normal adult height, should now receive paramount attention. In general, normal growth following solid
organ transplantation should be an achievable goal that results in normal adult height.
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Growth is frequently suboptimal in pediatric recipients
of kidney, liver, heart, lung or small bowel transplants.
Because the overwhelming majority of recipients are
prepubertal at the time of transplantation, optimizing
post-transplant growth to affect catch-up growth is impera-
tive if the target adult height is to be achieved. The
following will review the current data for growth after
successful solid organ transplantation in children.
& KIDNEY
What factors influence post-transplant growth in renal
allograft recipients? The three major factors are age at
transplantation, allograft function and corticosteroid dose.
Chronological age at transplantation is predictive of the
magnitude of post-transplant growth. The most recent data
from the North American Pediatric Renal Trials and
Collaborative Studies (NAPRTCS), which delineates growth
in children 0-1, 2-5, 6-12 and older than 12 years of age,
shows that the two youngest age groups of children, or
children less than 6 years of age, all exhibit catch-up growth
for the initial 1-2 years following transplantation and then
plateau after that time interval. However, children who are
greater than 6 years of age at the time of transplantation had
no catch-up growth. Therefore, older children do not exhibit
any catch-up growth, and their final adult height will be
determined by height at the time of transplantation (1).
Reduced renal allograft function has a significant effect on
growth velocity. Studies by Tejani et al. (2) almost two
decades ago showed that renal function has a profound
impact on growth, with a 0.17 decrease in the Z score (SDS)
being associated with a 1.0 mg/dl increase in the serum
creatinine level. These data indicate that as kidney function
deteriorates following renal transplantation, long-term
growth velocity will decrease. Likewise, the data emphasize
the need for optimal graft function to achieve the optimal
adult target height in pediatric renal allograft recipients.
Steroid dose also has a significant impact on growth in
pediatric allograft recipients. Switching from daily to every-
other-day steroids (3), steroid withdrawal and steroid
avoidance (4) have all been associated with improved
growth velocity. A randomized controlled trial of early
steroid withdrawal (TWIST Study) randomized 98 patients
to tacrolimus and mychophenolate mofetil with steroids
being discontinued on day 5 versus 98 patients randomized
to receiving tacrolimus, mychophenolate mofetil and ster-
oids with the steroids being tapered but continued at a daily
dose of 10 mg/m2. At 6 months, the standard deviation
score improved by 0.13 in the steroid withdrawal group
compared to continued steroid group (5). The patients
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enrolled in this study were primarily prepubertal patients.
All of the clinical parameters were similar in the two groups
except for increased infection and anemia rates in the
steroid withdrawal group. The long-term results of this
study have continued to show improved growth following
early steroid withdrawal without any adverse impacts on
allograft function. This regimen will likely become the
standard of care in the future. An alternative to steroid
withdrawal is total steroid avoidance. Preliminary studies
from the Stanford Group (4) seem to indicate that young
children experienced significant improvements in growth
velocity following steroid withdrawal compared to a
historical control group. Recently, Sarwal et al. (6) reported
the 3-year follow up from a multi-center, NIAID-sponsored
randomized controlled study of 130 children enrolled from
12 pediatric transplant centers in the United States. The
change in standard deviation score at 3 years for all of the
recipients was not different between the steroid-free and
the steroid-based groups. However, when the change in
standard deviation score at 3 years in the 27 children less
than 5 years of age was analyzed, there was a significant
difference in the growth velocity between the steroid-free
and steroid-based groups (p= 0.2). Biopsy-proven acute
rejection at 3 years was similar in the steroid-free (16.7%)
and steroid-based groups (17.1%). Patient survival was
100% in both groups, and graft survival was similar in both
groups (steroid free 95% and steroid based 90%). The
systolic blood pressure and cholesterol levels were lower in
the steroid-free group. This randomized controlled study
certainly indicates that steroid avoidance does not adversely
affect long-term graft function or increase the incidence of
biopsy-proven acute rejection. However, the impact on
growth was less than anticipated because the steroid-free
group only demonstrated an effect on growth in the
recipients less than 5 years of age. This study emphasizes
that there are factors other than steroids that affect growth
velocity and catch-up growth, especially in older pediatric
transplant recipients. A strategy to address modifiable
factors to enhance growth in older recipients will need to
be a significant focus in the future. The ultimate goal with
respect to growth in pediatric renal allograft recipients is
attaining a normal final adult height. Recent data from the
NAPRTCS registry (1) has shown that over the past quarter
century, there has been a significant increase in the average
final adult height of recipients entered into the registry.
From 1987 to 1991, those patients who reached adult height
had a standard deviation score of -1.93, whereas for the
patients who were entered into the registry between 2002
and 2010 and reached final adult height, the standard
deviation score was -0.94, representing an almost 1 standard
deviation improvement in final adult height over 15 to 20
years. This improvement certainly is a remarkable achieve-
ment and indicates that pediatric renal allograft recipients
now have final adult heights that are approaching their
target height.
One of the primary factors that have led to improved final
adult height has been that the height deficit at the time of
transplantation has improved markedly during the past
decade. The most recent NAPRTCS registry data1 indicate
that in 1987, the standard deviation score (Z score) for
patients at the time of transplantation was approximately
-2.5, whereas in patients who were transplanted in 2009, the
Z score at transplantation was between -1 and -1.5. Again,
over a quarter of a century, the standard deviation score for
children at the time of transplantation has improved more
than 1 standard deviation, which is similar to the improve-
ment in adult height over the same period for the same
patient population.
As indicated previously, the overwhelming majority of
children over 6 years of age at the time of transplantation do
not exhibit any catch-up growth following transplantation.
Therefore, if those patients are to achieve normal adult
height, some intervention to stimulate growth will be
required. This dilemma raises the question as to whether
the use of recombinant human growth hormone (rhGH)
improves growth in growth-retarded renal allograft recipi-
ents. There have been four (7-10) randomized controlled
studies that have studied rhGH treatment in growth-
retarded renal transplant patients. In all four studies, 1-
year growth significantly improved in the group receiving
rhGH compared to the control group. The growth velocity
in most of the studies doubled with rhGH treatment
compared to the control group. One concern regarding the
use of rhGH following renal transplantation has been prior
anecdotal information that rhGH may stimulate the immune
system and precipitate acute rejection. In all four studies,
there was no difference in the incidence of acute rejection in
the rhGH group compared to the control group.
A concern with one of the newer immunosuppressant
drugs, sirolimus, was that this agent could impair linear
growth in pediatric solid organ transplant recipients. Two
studies (11,12) have addressed this issue, which was raised
primarily because animal models have shown decreased
longitudinal growth due to sirolimus-mediated inhibition of
cell proliferation and vascular endothelial growth factor
expression in the long bone growth plate, which blocks
insulin-like growth factor (IGF) intracellular signaling in
chondrocytes (13). A study by Gonzalez et al. (11) evaluated
34 renal transplant recipients who received sirolimus for 24
months and compared their height standard deviation
scores to a control group. There was no difference in the
height standard deviation score between the sirolimus and
control groups at any time over the 24 months. However,
the change in height was significantly decreased in the
sirolimus group at all of the follow-up times compared to
the control group. The authors concluded that the growth
velocity was significantly decreased in the sirolimus group
compared to the control group. In contrast, Hymes and
Warshaw (12) studied 25 renal transplant recipients taking
sirolimus who were followed for 24 months and compared
their height standard deviation scores to a control group
receiving tacrolimus. The height standard deviation scores
were no different at baseline and 24 months between the
sirolimus and tacrolimus groups. The height standard
deviation score increased by 52% in the sirolimus group,
and the authors concluded that sirolimus does not impair
growth in renal allograft recipients.
& LIVER
Al-Sinani and Dhawan (14) summarized the current data
regarding growth following liver transplantation in 2009 by
evaluating 20 reports between 1987 and 2008. The number
of patients in each report varied from 21 to 236, and the
follow-up period in each report varied from 1 to more than
8 years. The number of recipients who exhibited catch-up
growth varied between 39 and 100%. The steroid regimen
used in the various reports was variable, including daily to a




tapered dose, every other day steroid therapy to steroid
withdrawal and steroid-free regimens. Therefore, specifi-
cally analyzing each group was quite difficult. However, the
authors attempted to identify the factors in these 20 reports
that impacted growth. Their assessment was that the steroid
dose impacted growth, with the cumulative dose, timing of
tapering and withdrawal and the presence of daily steroid
treatment having adverse impacts on growth. Height at the
time of transplantation also had an impact on catch-up
growth, with those who had decreased growth standard
deviation scores at the time of transplantation having
increased catch-up growth following transplantation. Age
was also a factor that impacted growth in children less than
2 years of age at the time of transplantation: these children
experienced increased catch-up growth. The primary
diagnosis (cholestasis, fulminant liver failure, sclerosis or
metabolic disease) had an impact on growth. Patients with
cholestasis or hepatitis had better post-transplant growth.
Graft dysfunction also impacted post-transplant growth,
with those liver transplant recipients who required re-
transplantation or developed post-transplant lymphoproli-
ferative disease (PTLD) having a reduced growth velocity
following transplantation. Alonso and colleagues (15)
reviewed the data for 1,143 recipients from the Studies of
Pediatric Liver Transplantation (SPLIT) registry. The stan-
dard deviation score was -1.55 at transplant, and at 24 and
36 months, the scores were -0.87 and -0.68, respectively.
These results demonstrate a significant improvement in the
height standard deviation score following liver transplanta-
tion. However, subsequent follow-up showed limited catch-
up growth after 36 months. The factors that negatively
impacted growth were more than 18 months of steroid
therapy following transplantation and the association of
primary metabolic or non-biliary cholestatic disease with
decreased catch-up growth.
Because the liver is thought to be less immunogenic than
other organs, steroid withdrawal has been used therapeu-
tically in pediatric liver transplant recipients in the past to
maximize linear growth. Five uncontrolled studies using
cyclosporine as the primary immunosuppressive agent have
withdrawn steroids between 3 and 58 months following
transplantation, and acute rejection occurred in 7 to 27% of
the patients. Chronic rejection that occurred in less than 18
months was present following steroid withdrawal in 4 to
13% of the patients and graft loss in 3 to 13%. More recently,
steroid withdrawal was attempted in three series of patients
with tacrolimus as the primary immunosuppressant (16-17).
In a study from Johns Hopkins (16), the steroid was
withdrawn at 6 months in 29 patients with a 29% acute
rejection rate. In Kyoto (17), the steroid was withdrawn at 8
months in 156 patients, all of whom were recipients of livers
from live related donors with a 14% acute rejection rate. In
Pittsburgh, the steroid was withdrawn within the first year
in 166 patients, and in 21% of these patients, reinstitution
was required within 5 years due to rejection. The SPLIT data
(15) indicate that at 24 months post-transplant, if steroids
are withdrawn less than 6 months, the increase in standard
deviation score (1.7 increase) was greater compared to
steroids being withdrawn after 18 months (0.9 increase).
These data indicate that steroid withdrawal, especially if
performed early, will result in an improved standard
deviation score and will potentially lead to improved adult
height. However, there is a risk of rejection and potential
graft loss with steroid withdrawal.
What can one anticipate as the final adult height in
pediatric liver transplant recipients? A 2008 study by
Scheenstra et al. (18) evaluated 23 recipients with a median
age of 13.3 years at transplantation. The standard deviation
scores were -1 at transplant and -1.4 at the final height, and
the median target height was -1.3. Additionally, 12 of the 23
had final adult heights below 1.3 standard deviations of
their target heights. These data indicate that a significant
number of liver transplant recipients cannot reach their
adult target heights. Because a number of liver transplant
recipients exhibit suboptimal post-transplant growth, one
could question whether or not there is any effective
treatment for improving growth in this population. Eight
recipients with standard deviation scores greater than 2
were treated with rhGH for more than 5 years. The standard
deviation scores improved from -3.6 to -2.7 (19). There were
no rejection episodes, and 1 patient who had elevated liver
enzyme levels prior to rhGH treatment was diagnosed with
chronic rejection at 3 years. This single study on a limited
number of patients would seem to indicate that severely
growth retarded liver transplant recipients could benefit
from prolonged rhGH treatment post-transplant without
any adverse impact on graft function.
& HEART
More than a decade ago, Chinnock and Baun (20)
evaluated heart transplant recipients at their institution
and delineated three factors that seemed to impact post-
transplant growth. These factors were the number of days
in the hospital during the first post-transplant year; the
number of treated rejection episodes after the first post-
transplant year; and mid-parental height, the genetic
growth potential for an individual, which is quite important
and had not been delineated by prior authors regarding
growth following other organ transplants. These authors
evaluated 77 infants who were transplanted at less than 6
months of age and received no maintenance steroid therapy.
Catch-up growth was quite prevalent during the first post-
transplant year, and only 6 of 51 patients who were more
than 5 years post-transplant had heights that were less than
the fifth percentile. This study demonstrated that the use of
a steroid-free maintenance protocol can lead to normal
growth for very young infants transplanted at less than 6
months of age. Peterson et al. (21) evaluated 46 heart
transplant recipients who were less than 11 years of age at
the time of transplantation. Those recipients showed no
significant change in the height standard deviation score up
to 24 months post-transplant. The authors noted that a
younger age at transplant had a positive impact on growth,
and the length of steroid treatment had a negative impact on
the change in the standard deviation score post-transplant.
Their current practice is to wean low-risk patients with no
rejection episodes off steroids at 1 year. More recently,
Bannister et al. (22), from Toronto Sick Kids, evaluated 130
heart recipients who were transplanted between 1990 and
2005 and had a mean follow-up of 4.4 years. Their mean
height Z score was unchanged from transplant to the last
measurement, and the mean was -1.3. The authors felt that
enteral feeding led to increased height standard deviation
scores in patients without sufficient caloric intake.
There are limited data on the use of rhGH in growth-
retarded pediatric heart transplant recipients. Mital et al. at
Columbia (23) reported 10 recipients with a mean age of 7.8
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years at transplant, a mean age at the initiation of rhGH
treatment of 13 years and a mean duration of rhGH
treatment of 2.5 years. The growth velocity increased from
2.5 cm per year at baseline to 8.6 cm per year during rhGH
treatment. The authors noted increases in left ventricular
shortening fraction, left ventricular volume and cardiac
output in the patients who received rhGH treatment. The
left ventricular volume remained increased following the
discontinuation of rhGH; therefore, this change was thought
to be physiologic and not pathologic.
& LUNG
Recently, Elizur et al. (24) from St. Louis Children’s
Hospital reported on 36 infants ,1 year of age and 26
toddlers 1-3 years of age who underwent lung transplanta-
tions between 1990 and 2004. At transplant, the height
standard deviation scores were -1.76 for infants and -1.72 for
toddlers. At 1, 3 and 5 years post–transplant, the standard
deviation scores became more negative (-1.89, -1.91 and
-2.14, respectively). Obviously, this report indicates that
catch-up growth does not occur. Indeed, increased growth
retardation occurs following lung transplantation. Thus,
rhGH has been used in a small series at St. Louis Children’s
Hospital. Sweet and his colleagues (25) reported that 8 of 9
lung transplant recipients who received rhGH developed
bronchiolitis obliterans syndrome, which was a higher
incidence compared to the group who did not receive
rhGH. Therefore, Sweet and his colleagues caution the use
of rhGH to enhance growth velocity in lung transplant
recipients.
& SMALL BOWEL
The current data on growth in small bowel recipients was
delineated by Nayyar and colleagues (26). Of 76 small bowel
transplant recipients who received transplants at a mean
age of 2.6 years, 34 received standard immunosuppression
with tacrolimus and steroids, and 42 underwent a combina-
tion of anti-thymocyte globulin induction followed by
tacrolimus and only received steroids for acute rejection.
Additionally, 48% of the patients who received anti-
thymocyte globulin remained steroid-free during the fol-
low-up period, and the height standard deviation score
improved at 2 years in the steroid-free group. These data
seem to indicate that steroid-free immunosuppression has
beneficial effects in the small bowel transplant population.
& CONCLUSION
There are universal factors that impact growth velocity,
catch-up growth and final adult height in all pediatric solid
organ transplant recipients. The height at the time of
transplant is certainly an important factor, with more severe
growth retardation at transplant leading to a potential for
greater catch-up growth following transplant. A normal
target height at transplant has the potential to result in
normal final adult height. The latter has certainly been
shown in the renal transplant population.
The age at transplant also impacts growth, with younger
recipients tending to be more growth-retarded at trans-
plant; therefore, these patients may exhibit greater catch-up
growth.
Likewise, graft dysfunction impacts growth, with the
number of acute rejection episodes, number and length of
hospitalizations, need for re-transplantation and need for
surgical re-exploration all having adverse effects on growth.
Renal dysfunction, whether in renal allograft recipients or
in recipients of other solid organ transplants, may have
adverse impacts on growth. In renal allograft recipients,
primary renal dysfunction certainly has been associated
with an adverse effect on growth. In recipients of other solid
organ transplants, renal dysfunction secondary to drug
toxicity (i.e., calcineurin inhibitors, antibiotics and antivir-
als) can have adverse impacts on growth.
Bone dysfunction may impact growth, whether there is a
persistent bone abnormality resulting from the primary
disease or acquired bone dysfunction following solid organ
transplantation.
Corticosteroids can certainly impact growth in all
pediatric solid organ transplant recipients. Steroid-free
regimens are optimal, with steroid withdrawal being a
secondary option. In the studies where steroid withdrawal
was effective, it was noted that earlier withdrawal was
better. Receiving every-other-day steroid therapy had a
positive impact on growth; however, adherence is a concern
when every-other-day treatment is used. One of the major
factors that may adversely affect the ultimate adult height is
a suboptimal pubertal growth spurt. This spurt occurs to a
significant degree in renal allograft recipients and may
also occur in other solid organ transplant recipients. One
potential therapeutic option to enhance pubertal growth is
the use of rhGH to enhance the magnitude of the pubertal
growth spurt; however, to my knowledge, there are no
studies that have addressed this issue. Importantly, when
one is determining the factors that affect growth following
transplantation, genetic potential is a major factor that will
determine target height. Thus, one should determine the
mid-parental height when determining the anticipated
target height for any recipient. In addition, one should also
be cognizant that if the patient has significant growth
retardation there may be a genetic abnormality causing
primary short stature rather than the growth retardation
being a consequence of the primary disease or other factors
following organ transplantation.
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